Management of Myeloproliferative Disorders and Chronic Myeloid Leukemia Ayalew Tefferi The myeloproliferative neoplasms (MPN) are considered separate from the myelodysplastic syndromes (MDS) and are further classified into classic and nonclassic…
Myelodysplastic Syndromes Christopher R. Cogle Rami S. Komrokji Alan F. List The myelodysplastic syndromes (MDS) comprise a spectrum of neoplastic hematopoietic stem cell disorders that share the features of ineffective…
Acute Myeloid Leukemia Radwan F. Khozouz Carl E. Freter Acute myeloid leukemia (AML) accounts for 90% of acute leukemias diagnosed in adults, while comprising only a minority (15% to 20%)…
Chronic Lymphocytic Leukemia Preetesh Jain Kanti R. Rai CHRONIC LYMPHOCYTIC LEUKEMIA Introduction Chronic lymphocytic leukemia (CLL) is the most common leukemia (25% to 30%) in the Western world. The incidence…
Non-Hodgkin Lymphoma Philip J. Bierman James O. Armitage Non-Hodgkin lymphomas are a group of related malignancies of lymphocytes. Some lymphomas are among the most rapid growing and aggressive of all…
Chemotherapy of Hodgkin Lymphoma Anne Hudson Blaes Bruce A. Peterson In the four decades since the introduction of MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) by DeVita and coworkers,1 significant advances…
Section VI Chemotherapy of Hematologic Malignancies Chemotherapy for Childhood Leukemia Barbara A. Gruner The dramatic improvement in outcome for children with acute lymphoblastic leukemia (ALL) has been one of the…
Chemotherapy for Pediatric Solid Tumors Barbara A. Gruner Pediatric cancers are rare, with an incidence of 169.1 per 1,000,000 for children under the age of 19 in the United States…
Chemotherapy of Bone and Soft Tissue Sarcomas Rashmi Chugh Scott M. Schuetze Sarcomas are an uncommon group of malignancies that arise from connective tissue and can be located in any…
Chemotherapy of Carcinoma of Unknown Primary Site John D. Hainsworth F. Anthony Greco Cancer of unknown primary site (CUP) is a common clinical syndrome, accounting for 3% to 5% of…
